Kaufman: Mental Health, Drug Abuse Cuts Are Hurting Community
Kaufman: Mental health, drug abuse cuts are hurting community
Filed under: drug treatment program statistics
The statistics point to the fact that we are not adequately serving this population in need. In 2011, 21.6 million persons aged 12 or older needed treatment for an illicit drug or alcohol use problem. Of these, 2.3 million received treatment at a …
Read more on Sun-Sentinel
Keeping Parolees Out of Prison
Filed under: drug treatment program statistics
Encouraged by the federal Second Chance Act of 2008, which aims to promote correctional reform, several states have cut recidivism by giving newly released inmates access to drug treatment or mental health care, focusing parole supervision on the …
Read more on New York Times
In St. Petersburg, Melanie Bevan didn't skip a beat in rising to assistant …
Filed under: drug treatment program statistics
Women made up less than 12 percent of the staff in 1990, according to police statistics. They account for 16.5 percent of the force today. Bevan recalls one night when a … In the early 2000s, Bevan started the agency's street crimes unit, a squad of …
Read more on Tampabay.com
FDA Drug Info Rounds, July 2012: Accelerated Approval Program – The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious diseases, and that fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker that is used in clinical trials as an indirect or substitute measurement that represents a clinically meaningful outcome. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market. For more information, please see our website: www.fda.gov [vpdrugs]